Edition:
United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,298.70INR
24 Nov 2017
Change (% chg)

Rs-12.95 (-0.56%)
Prev Close
Rs2,311.65
Open
Rs2,311.00
Day's High
Rs2,324.05
Day's Low
Rs2,290.00
Volume
29,923
Avg. Vol
74,704
52-wk High
Rs3,247.00
52-wk Low
Rs1,901.65

Latest Key Developments (Source: Significant Developments)

Indivior to appeal court rulings ANDA litigation
Friday, 1 Sep 2017 02:00am EDT 

Sept 1 (Reuters) - Indivior Plc :INDIVIOR TO APPEAL COURT RULINGS ANDA LITIGATION.INDIVIOR RESPONDS TO COURT RULINGS IN ANDA LITIGATION AND ANNOUNCES INTENTION TO APPEAL.US DISTRICT COURT FOR DISTRICT OF DELAWARE HAS FOUND ASSERTED CLAIMS OF U.S. PATENT NOS. 8,017,150; 8,603,514; 8,900,497 VALID.US DISTRICT COURT FOR DISTRICT OF DELAWARE FOUND DR. REDDY'S DOES NOT INFRINGE ANY ASSERTED CLAIMS OF PATENTS.US DISTRICT COURT FOR DISTRICT OF DELAWARE FOUND WATSON (ACTAVIS) AND PAR DO NOT INFRINGE ASSERTED CLAIM OF '497 PATENT.COURT HAS ALSO ISSUED A SEPARATE RULING DENYING WATSON'S AND PAR'S MOTIONS TO REOPEN COURT'S JUNE 2016 JUDGMENT.COURT'S RULING ENJOINING MARKETING APPROVAL AND SALE OF WATSON'S AND PAR'S PROPOSED GENERIC PRODUCTS UNTIL EXPIRATION OF '514 PATENT IN 2024 REMAINS IN PLACE.  Full Article

Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation
Wednesday, 30 Aug 2017 04:05pm EDT 

Aug 30 (Reuters) - Vivus Inc ::Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation.Vivus Inc - ‍settlement permits Dr. Reddy's to begin selling a generic version of qsymia on June 1, 2025, or earlier under certain circumstances​.Vivus - ‍in event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of generic version of qsymia​.  Full Article

Dr.Reddy's Laboratories launches Cefixime for oral suspension, usp in the U.S.
Monday, 28 Aug 2017 01:46am EDT 

Aug 28 (Reuters) - Dr.Reddy's Laboratories Ltd :Says launch of Cefixime for oral suspension, usp in U.S. Market.  Full Article

Dr.Reddy's Laboratories says class action lawsuit filed against co
Monday, 28 Aug 2017 12:39am EDT 

Aug 28 (Reuters) - Dr.Reddy's Laboratories Ltd ::Says law firm representing an investor in co filed class action lawsuit against company its CEO, and CFO.Co cannot comment on the specific allegations in the pending litigation.Says has not yet been served with the lawsuit.Says "believes the asserted claims to be without merit".Class action lawsuit filed in U.S. district court of New Jersey for alleged violations of U.S. federal securities laws.  Full Article

Dr.Reddy's Labs says ‍GMP compliance certificate relating to Hyderabad unit not renewed
Thursday, 10 Aug 2017 05:06am EDT 

Aug 10 (Reuters) - Dr.Reddy's Laboratories Ltd :‍GMP compliance certificate relating to co's manufacturing unit in Hyderabad not renewed consequent to recent inspection of plant​.Pending revocation of non-compliance notification, plant will not be able to make despatch to European Union until next inspection.  Full Article

India's Dr Reddy's expects U.S. "adverse pricing environment" to persist
Thursday, 27 Jul 2017 09:54am EDT 

July 27 (Reuters) - India's Dr Reddy's Laboratories ::COO Abhijit Mukherjee says expects adverse pricing environment in U.S. to persist.COO Mukherjee says "remain optimistic on 2-3 launches per quarter" in U.S..India's Dr Reddy's labs COO Mukherjee says experiencing "a lot of transition challenges" due to GST.Dr Reddy's Labs exec says improving manufacturing processes and automating procedures will take a few more quarters to complete.  Full Article

Dr.Reddy's Laboratories, CHD Bioscience announce global license & commercialization deal
Thursday, 27 Jul 2017 06:55am EDT 

July 27 (Reuters) - Dr.Reddy's Laboratories Ltd :Co, CHD Bioscience announce global license & commercialization deal for phase III clinical trial candidate for mitigation of surgical site infections.Co to get equity in CHD valued at $30 million on IPO of CHD or minimum of $30 million in cash in 18 months of execution of agreement.Says will also receive additional milestone payments of $40mln upon USFDA approval.  Full Article

Dr.Reddy's Laboratories June-qtr consol profit falls about 57 pct
Thursday, 27 Jul 2017 04:43am EDT 

July 27 (Reuters) - Dr.Reddy's Laboratories Ltd :June quarter consol net profit after tax and share of profit of associates 666 million rupees versus profit of 1.54 billion rupees last year.Says Q1 results of FY18 "been below expectations".Dr.Reddy's Laboratories-headwinds as price erosion due to U.S. customer consolidation continue.Consol june quarter total revenue from operations 33.33 billion rupees versus 32.45 billion rupees last year.Lower contribution from new product launches in U.S. and GST in India also impacted performance in quarter.  Full Article

Dr.Reddy's Labs says audit of Mexican plant by USFDA completed with zero observations
Friday, 21 Jul 2017 01:27am EDT 

July 21 (Reuters) - Dr.Reddy's Laboratories Ltd :Says audit of our API Cuernavaca plant at Mexico, by US FDA, has been completed with zero observations.  Full Article

Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets
Thursday, 15 Jun 2017 02:03am EDT 

June 15 (Reuters) - Dr.Reddy's Laboratories Ltd :Dr.Reddy's Laboratories clarifies on news item, "Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US"..Says voluntarily recalled Cipla-made zenatane capsule from US markets.Recall of prodcuts is a usual activity in normal course of business operations.Says overall impact on co's financials of recall not likely to be significant.  Full Article

BRIEF-Dr.Reddy's Laboratories gets EIR from US FDA for Duvvada facility

* Says got EIR from US FDA for formulations manufacturing facility at Duvvada, Vishakhapatnam‍​